---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-023172"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T00:56:47.124205+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics secures up to $2M nondilutive funding from Foundation Fighting Blindness for MERTK gene therapy

## Summary
- Up to $2,000,000 nondilutive funding from Foundation Fighting Blindness Retinal Degeneration Fund for MERTK gene therapy program.
- $1,000,000 disbursed upfront; up to $1,000,000 additional upon milestone achievement.
- Company must meet development milestones; failure triggers obligation to out-license program.
- Regulatory milestone triggers payment equal to total funded amount; tiered royalties until 300% repayment.
- On change of control, RDF may require buy-out at 100% of funded amounts.

## SEC filing metadata
- accession: 0001140361-25-023172
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125023172/0001140361-25-023172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125023172/ef20050845_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-023172
- JSON: https://secwatch.observer/filing/0001140361-25-023172.json
- Plain text: https://secwatch.observer/filing/0001140361-25-023172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.